Today: February 28, 2017, 12:15 am

"EpiCast Report: Migraine - Epidemiology Forecast to 2023" now available at Fast Market Research

New Pharmaceuticals research report from GlobalData is now available from Fast Market Research 2014-03-22 11:31:03
Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following symptoms: nausea; vomiting; and increased sensitivity to light, sound and smell (Bigal and Lipton, 2006). Because migraine is one of the most prevalent types of headache, there is a substantial economic and social burden associated with the condition worldwide, and it is therefore recognized as a high-priority public health problem by the World Health Organization (WHO) (Leonardi et al., 2005; Lusic, 2001). The Global Burden of Disease (GBD) study in 2010 ranks migraine as the first among the neurological disorders (Leonardi and Raggi, 2013).

In 2023, GlobalData epidemiologists forecast that the total prevalent cases of migraine in the 7MM remained almost the same, with 75.83 million total prevalent cases in 2013 and 76.38 million total prevalent cases, with an annual growth rate (AGR) of 0.07% in the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of migraine, with 29.61 million total prevalent cases in 2013 and 31.13 million total prevalent cases in 2023.

Full Report Details at
- ..

GlobalData epidemiologists obtained total prevalence data for migraine from peer-reviewed journals and population-based studies in the respective markets and used consistent methodology to ensure comparability of results. Furthermore, GlobalData epidemiologists made a meaningful assumption that the age- and sex-specific total prevalence of migraine in the 7MM would remain constant throughout the forecast period because epidemiologic literature suggests relatively stable trends in the prevalence of migraine worldwide, thereby providing a realistic and meaningful forecast for the age- and sex-specific total prevalent cases of migraine in the 7MM.


* The Migraine EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of migraine in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of migraine segmented by age (beginning at 18 years and ending at 80 years and older), sex, and the number of total prevalent cases of migraine with aura and without aura in these markets.
* The migraine epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
* The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Get this Report

* Develop business strategies by understanding the trends shaping and driving the global migraine market.
* Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans.
* Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for migraine therapeutics in each of the markets covered.
* Identify the number of migraine cases with aura and without aura.

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.2.1 Female sex and family history are interrelated risk factors of migraine
3.2.2 People with migraine also suffer from several comorbidities
3.3 Global Trends
3.3.1 US
3.3.2 5EU
3.3.3 Japan
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Migraine (2013-2023)
3.5.1 Total Prevalent Cases of Migraine
3.5.2 Age-Specific Total Prevalent Cases of Migraine
3.5.3 Sex-Specific Total Prevalent Cases of Migraine
3.5.4 Age-Standardized Total Prevalence of Migraine
3.5.5 Total Prevalent Cases of Migraine with Aura and Migraine without Aura
3.6 Discussion
3.6.1 Conclusions on Epidemiological Trends
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologists
4.2.2 Reviewers
4.2.3 Global Director of Epidemiology and Health Policy
4.2.4 Global Head of Healthcare
4.3 About GlobalData
4.4 About EpiCast
4.5 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Migraine
Table 2: Prevalence of the Most Frequent Comorbidities in People with and without Migraine, Ages ≥18 Years, Both Sexes
Table 3: One-Year Total Prevalence (%) of Migraine in the 5EU
Table 4: Lifetime Total Prevalence (%) of Migraine in the 3EU
Table 5: Criteria Proposed by the Second Edition of the International Classification of Headache Disorders (ICHD-2)
Table 6: Epidemiological Sources of Total Prevalence Data Used in the Analysis for Migraine and its Subtypes (Migraine with Aura and Migraine without Aura)
Table 7: 7MM, Total Prevalent Cases of Migraine, Ages ≥18 Years, Both Sexes, N, 2013-2023
Table 8: 7MM, Total Prevalent Cases of Migraine, by Age, Both Sexes, N, (Row %), 2013
Table 9: 7MM, Total Prevalent Cases of Migraine, by Sex, Ages ≥18 years, N (Row %), 2013
Table 10: 7MM, Total Prevalent Cases of Migraine with Aura and Migraine without Aura, Ages ≥18 Years, Both Sexes, N, Row (%), 2013

List of Figures

1.2 List of Figures

Full Table of Contents is available at:

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Press Information

Published by
Bill Thompson

# 945 Words
Related Articles
More From Health
Genf20 Plus - New Facts Now Released
GenF20 Plus has now been introduced as the HGH-releasing solution that restores HGH levels naturally and safely. The aim of [..]
Hot Flashes and Night Sweats: Sage Leaf [..]
Sage is a delicious herb used in cooking, particularly with poultry and pasta sauces, and it has a long history [..]
Why are most women disappointed in bed [..]
In a recent study 384 women asked “What can make sex an unpleasant experience for you?”. 84.9% answered that the [..]
Active Clinics recently introduced cryotherapy treatments to The Midlands in UK to help individuals with various skin problems look [..]
DERMATOLOGIE- CANCER : Des doutes sur des grains [..]
DERMATOLOGIE- CANCER : Des doutes sur des grains de beauté ? Plus besoin d’une biopsie invasive ! Le Centre Médical Incorpore [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.